Compare Ginkgo Bioworks Holdings Inc (DNA) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs SkyWest Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.11 (market cap $590.53M), while SkyWest Inc trades at $100.37 (market cap $3.85B). The key difference: SkyWest Inc is far larger — about 6.5× Ginkgo Bioworks Holdings Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | SKYW | |
|---|---|---|
Market Cap | $590.53M | $3.85B |
Sector | Health | Technology |
52-Week High | $16.14 | $123.72 |
52-Week Low | $5.48 | $78.40 |
Enterprise Value | $627.78M | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
SkyWest (SKYW) trades at $97.78, down 1.95% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong fundamentals with a P/E of 9.32 and net income margin of 10.42%, supported by recent earnings beats. Analyst consensus is bullish with a $109.33 price target. Recent news includes a key executive appointment and attention to fuel cost pressures in the airline industry.
The outlook for SKYW is positive given its attractive valuation and profitability, but risks include rising fuel expenses and industry volatility. With no sell ratings and 56% buy consensus, the stock presents a compelling opportunity for upside, though investors should monitor cost management and quarterly results closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
